StreetAlpha.app
Home › Stocks › NBP

NovaBridge Biosciences (NBP)

$0.83
▼ −5.66%
LAST CLOSE · NOV 20

NovaBridge Biosciences develops drug candidates for cancer and eye disease, led by givastomig for gastric cancer. It last closed at $0.83 on Nov 20, down 5.66% on the day. Over the last 12 months NBP insiders bought $663K of stock on the open market and sold $154K, according to SEC Form 4 filings.

AI Auto Pilots
Is NBP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NBP.

Key Stats

Last 12 months
Results
Net income
−$46.3M
Balance sheet
Cash & equivalents
$210.6M
At Dec 31
Shareholder equity
$230.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$365.9M−$365.9MFY2021FY2022: −$371.1M−$371.1MFY2022FY2023: −$207.7M−$207.7MFY2023FY2024: −$22.2M−$22.2MFY2024FY2025: −$46.3M−$46.3MFY2025

From NBP's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jun 16). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Technical Analysis

NBP · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 18% below its 20 day and 50% below its 50 day average. It is 138% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the Pivot S1 at $0.78, and the nearest resistance the Pivot at $0.88.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 10.1%/day
Key levels
$5.1952 week high+525.3%
$1.98200 day average+138.6%
$1.53100 day average+84.3%
$1.44Swing high (Oct 6)+73.5%
$1.2450 day average+49.4%
$0.9820 day average+18.1%
$0.93Pivot R1+12.0%
$0.88Pivot+6.0%
$0.83Last close
$0.78Pivot S1−6.0%
$0.7552 week low−9.6%
$0.75Swing low (Nov 17)−9.6%
Indicators
RSI (14)30.79Weak, oversold below 30Neutral
MACD-0.13Above its signal lineBullish
Stochastic28.2Middle of its rangeNeutral
ADX (14)43.3Strong downtrend
Williams %R-75.5Oversold below −80, overbought above −20Neutral
CCI (20)-51.3Oversold below −100, overbought above 100Neutral
Rate of change−8.7%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NBP

What happened before

See how NBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NBP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NBP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NBPHow many large options trades hit NBP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NBP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●23 buying vs 22 selling
  • ▼Held by funds -0.7 pts
  • ▼Funds holding -1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4849−2.0%
In funds' top 10110.0%
Held by funds8.6%9.3%−0.7 pts
New / increased9 / 1412 / 13−8.0%
Reduced / sold out13 / 911 / 110.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NBP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NBP Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$663K2 buys · 1 insider
Sold$154K7 sales · 3 insiders
2026-04 bought $577K2026-05 sold $43K2026-06 sold $19K2026-07 sold $4K2026-08 sold $3K2026-09 sold $86K2026-11 bought $86KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Mark Arnold HaglerChief Commercial OfficerBuy230,000$0.37$86K
Sep 18Phillip Andrew DennisChief Medical OfficerSale8,209$0.71$6K
Sep 9Sean Wuxiong CaoChief Bus. Development OfficerSale107,978$0.74$80K
Aug 31Cong Claire XuEVP, Clinical DevelopmentSale3,282$0.79$3K
Jul 6Cong Claire XuSVP, Clinical DevelopmentSale4,485$0.89$4K
Jun 18Phillip Andrew DennisChief Medical OfficerSale8,494$0.66$6K
Every insider buy and sale for NBP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NBP insider trades →

From SEC Form 4 filings by NBP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBP is in one of them and how their past NBP trades turned out.

NBP in the AI portfolios
Loading…

NBP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NBP in an article yet. Here's the latest on the wider market.

NBP in the news

About NovaBridge Biosciences

NovaBridge Biosciences is a biotechnology company based in Rockville, Maryland, that develops drug candidates for cancer and eye disease. Its lead program is givastomig, an antibody therapy being tested for gastric cancer and other tumors that express the CLDN18.2 protein. The company is also developing VIS-101, a candidate for wet macular degeneration and diabetic macular edema. Its treatments are aimed at patients worldwide.

Headquarters
Rockville, MD